ACORDA THERAPEUTICS INC (ACOR)       0.98  -0.01 (-1.01%)

0.98  -0.01 (-1.01%)

US00484M6012 - Common Stock


Fundamental Rating

2

Overall ACOR gets a fundamental rating of 2 out of 10. We evaluated ACOR against 641 industry peers in the Biotechnology industry. Both the profitability and financial health of ACOR have multiple concerns. ACOR is valued expensive and it does not seem to be growing.

Note: ACOR has only limited data available, so a full analysis was not possible, which makes the total rating unfair.




Profitability

Profitability Rating

1

The Piotroski-F score of ACOR is 4.00. This is a neutral score and indicates average health and profitability for ACOR.

VS Industry

Valuation

Valuation Rating

3

When comparing the current price to the book value of ACOR, it is valued rather cheaply. It is trading at 0.31 times its book value.
Compared to an average industry price book ratio of 1.91, ACOR is valued rather cheaply. On top of this, ACOR is cheaper than 95% of the companies listed in the same industry.

ACOR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
VS Industry

Price/Book (0.31) VS Industry: 95% outperformed.

440.81
0.07

Growth

Growth Rating

2

ACOR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.00%, which is quite impressive.
The Revenue has decreased by -4.82% in the past year.

Measured over the past 5 years, ACOR shows a very negative growth in Revenue. The Revenue has been decreasing by -24.31% on average per year.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A 27% N/A N/A N/A N/A
Revenue-24.31% -35.06% -4.82% N/A N/A N/A N/A

Health

Health Rating

2

A Current Ratio of 1.71 indicates that ACOR should not have too much problems paying its short term obligations.
A Quick Ratio of 1.34 indicates that ACOR should not have too much problems paying its short term obligations.
The Piotroski-F score of ACOR is 4.00. This is a neutral score and indicates average health and profitability for ACOR.
Compared to an average industry Current Ratio of 6.18, ACOR is worse placed to pay its short term obligations than its industry peers. 87% of its industry peers have a better Current Ratio.

Compared to an average industry Quick Ratio of 6.05, ACOR is worse placed to pay its short term obligations than its industry peers. 90% of its industry peers have a better Quick Ratio.
Compared to an average industry Debt to Equity Ratio of 0.00, ACOR is requires more financing than its industry peers. 97% of its industry peers have a better Debt to Equity Ratio.
Based on the Altman-Z score of -3.33, we must say that ACOR is in the distress zone and has some risk of bankruptcy.
Compared to an average industry Altman-Z score of -0.14, ACOR is in worse financial health than its industry peers.
VS Industry

Debt/Equity (2.48) VS Industry: 3% outperformed.

15.37
0.00

Quick Ratio (1.34) VS Industry: 10% outperformed.

0.04
84.53

Current Ratio (1.71) VS Industry: 13% outperformed.

0.08
85.09

Altman-Z (-3.33) VS Industry: 33% outperformed.

-2,797.49
667.93

Dividend

Dividend Rating

0

ACOR does not give a dividend.

ACORDA THERAPEUTICS INC0.98

NASDAQ:ACOR (2/7/2023, 7:22:19 PM)-0.01 (-1.01%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) N/A N/A Earnings (Next) 03-07 2023-03-07/amc
Inst Owners 25.86% Inst Owner Change 0.29%
Ins Owners 0.62% Ins Owner Change -2.01%
Market Cap 23.85M Analysts 82.86
Price Target 10.2 (940.82%)

Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y) N/A DP N/A
Div Incr Years N/A Div Non Decr Years N/A
Ex-Date N/A

Surprises & Revisions
EPS beat(2) N/A Avg EPS beat(2) N/A
Min EPS beat(2) N/A Max EPS beat(2) N/A
EPS beat(4) N/A Avg EPS beat(4) N/A
Min EPS beat(4) N/A Max EPS beat(4) N/A
Revenue beat(2) N/A Avg Revenue beat(2) N/A
Min Revenue beat(2) N/A Max Revenue beat(2) N/A
Revenue beat(4) N/A Avg Revenue beat(4) N/A
Min Revenue beat(4) N/A Max Revenue beat(4) N/A
PT rev (1m) 0% PT rev (3m) 0%
EPS NQ rev (1m) N/A EPS NQ rev (3m) N/A
EPS NY rev (1m) N/A EPS NY rev (3m) N/A
Revenue NQ rev (1m) N/A Revenue NQ rev (3m) N/A
Revenue NY rev (1m) N/A Revenue NY rev (3m) N/A

Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.19
P/FCF N/A
P/OCF N/A
P/B 0.31
P/tB N/A
EV/EBITDA N/A
EPS(TTM) -6.03 EY N/A
EPS(NY) N/A Fwd EY N/A
FCF(TTM) -1.11 FCFY N/A
OCF(TTM) -1.1 OCFY N/A
SpS 5.1 BVpS 3.11
TBVpS -9.74 PEG (NY) N/A
PEG (5Y) N/A

Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM N/A
GM 75.84%
ROICexgc(3y) N/A ROICexcg growth 3Y N/A
ROICexcg growth 5Y N/A ROICexc(3y) N/A
ROICexc growth 3Y N/A ROICexc growth 5Y N/A
OM growth 3Y N/A OM growth 5Y N/A
PM growth 3Y N/A PM growth 5Y N/A
GM growth 3Y -4.66% GM growth 5Y -2.89%
F-Score 4 Asset Turnover 0.32

Health
Industry RankSector Rank
Debt/Equity 2.48
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.78%
Profit Quality N/A
Current Ratio 1.71
Quick Ratio 1.34
Altman-Z -3.33
F-Score 4 WACC 1.58%
ROIC/WACC N/A Cap/Depr(3y) 90.83%
Cap/Depr(5y) 125.87% Profit Quality(3y) N/A
Profit Quality(5y) N/A

Growth
EPS 1Y 27% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q 61.54%
EPS Next Y N/A EPS Next 2Y N/A
EPS Next 3Y N/A EPS Next 5Y N/A
Revenue growth 1Y -4.82% Revenue growth 3Y -35.06%
Revenue growth 5Y -24.31% Revenue growth Q2Q 6.53%
Revenue Next Year N/A Revenue Next 2Y N/A
Revenue Next 3Y N/A Revenue Next 5Y N/A
EBIT growth 1Y 45.55% EBIT growth 3Y N/A
EBIT growth 5Y N/A EBIT Next Year N/A
EBIT Next 3Y N/A EBIT Next 5Y N/A
FCF growth 1Y 70.67% FCF growth 3Y N/A
FCF growth 5Y N/A OCF growth 1Y 63.85%
OCF growth 3Y N/A OCF growth 5Y N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA